Pfizer has claimed that its new experimental COVID-19 pill has shown promise against the Omicron variant. The company has shared the results of its recent trial with 2,250 people which reportedly reduced hospitalizations and deaths by about 89 percent among high-risk adults. The company also announced that they tested the drug against a man-made version of a key protein that Omicron uses to reproduce itself. The company also expressed hopes of authorization from the US FDA, as that would help these pills to be picked for covid treatments. The company also disclosed that they are planning to research the pill on lower-risk adults, including a subset who are vaccinated.